COVID-19 Treatment

If you are recently diagnosed with COVID-19, there are several home care and medical therapeutic options to manage symptoms and potentially reduce severity of illness. 

Self-care at home

If you test positive for COVID-19, or you are presumed to have COVID-19, but you don’t have severe enough symptoms to go to the hospital, there are many ways to manage symptoms at home and with over-the-counter medication. 

  • Rest.
  • Stay hydrated.
  • Take over-the-counter medication or use home remedies for various symptoms.
    1. Fever/body aches: Acetaminophen (Tylenol), naproxen (Aleve), ibuprofen (Advil, Motrin).
    2. Cough/congestion: Cough suppressant and/or expectorant (Mucinex, Robitussin), drink hot beverages (tea, broth), suck on cough drops or hard candy.
  • Monitor your symptoms. If you start to experience severe symptoms, contact your healthcare provider immediately. Severe symptoms include:
    1. Shortness of breath.
    2. Fever over 104 degrees Fahrenheit.
    3. Persistent pain or pressure in the chest.
    4. Confusion or inability to wake up.
    5. Lips or face are turning blue.

Therapeutics

Therapeutics are available (by prescription) for preventing and treating COVID-19 in specific at-risk populations. Patients can discuss with their healthcare provider if they are a candidate for therapeutic medications, and if they are available locally. 

Contact a healthcare provider right away after a positive test to determine if you are eligible for treatment, even if your symptoms are mild. Don’t delay. Treatment must be started within the first few days of when your symptoms started to be effective.

COVID-19 therapeutics differ in efficacy, route of administration, risk profile and whether they are authorized by the Food and Drug Administration (FDA) for adults only or adults and certain pediatric populations. Efficacy of treatments is closely monitored as new variants and subvariants emerge.

COVID-19 treatment allocation is determined at the federal and state levels, and Springfield-Greene County Health does not have control over availability or location of specific medications. The DHSS Test to Treat program provides designated testing sites where people can determine their eligibility for treatment and get a prescription if they qualify upon a positive COVID-19 test result. Locate these sites at the DHSS COVID-19 Test to Treat Locator or by calling 1-800-232-0233.


Antivirals

  • Paxlovid (nirmatrelvir/ritonavir): Oral antiviral for treatment of mild to moderate COVID-19; EUA for adult and pediatric patients (at least age 12 and weighing at least 40 kg) at high risk for progressing to severe COVID-19 infection.
  • Molnupiravir: Oral antiviral for treatment of mild to moderate COVID-19; EUA for adults at high risk for progressing to severe COVID-19 infection, and for whom alternative treatment options authorized or approved by the FDA are not accessible or clinically appropriate.
  • VEKLURY (remdesivir): IV antiviral for treatment of mild to moderate COVID-19; FDA Approved for adults and pediatric patients (at least age 12 and weighing at least 40 kg) who are (1) hospitalized or (2) not hospitalized and at high risk for progressing to severe COVID-19 infection; EUA for pediatric patients weighing 3.5 kg to less than 40 kg or pediatric patients less than 12 years of age (weighing at least 3.5 kg) who are (1) hospitalized or (2) not hospitalized and at high risk for progressing to severe COVID-19 infection.

Monoclonal antibodies (mAb):

  • *Sotrovimab: IV infusion for treatment of mild to moderate COVID-19; Emergency Use Authorization (EUA) for adult and pediatric patients (at least age 12 and weighing at least 40 kg) at high risk for progressing to severe COVID-19 infection. *Not recommended for use while BA.2 is dominant subvariant
  • Bebtelovimab: IV injection for treatment of mild to moderate COVID-19; EUA for adult and pediatric patients (at least age 12 and weighing at least 40 kg) at high risk for progressing to severe COVID-19 infection and for whom alternative treatment options authorized or approved by the FDA are not accessible or clinically appropriate. 
  • Evusheld (tixagevimab/cilgavimab): Intramuscular injection for pre-exposure prophylaxis (PrEP), for people not currently infected with SARS-CoV-2 and who have not had a known recent exposure. EUA for adult and pediatric patients (at least age 12 and weighing at least 40 kg) who are moderately to severely immunocompromised or for those who any EUA or approved vaccine is not recommended.  

View treatment options, efficacy, requirements and more side-by-side from the DHSS.